Results 11 to 20 of about 14,917 (240)
Hypomethylating Agents in Oncohematology [PDF]
Клиническая онкогематология, 2016 The review describes epigenetic processes, including methylation of nuclear and mitochondrial DNA, as well as RNA. It dwells on mechanisms of demethylation and corresponding medicinal products.
Anton Dmitrievich Shirin +1 more
doaj +2 more sources
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS [PDF]
Mediterranean Journal of Hematology and Infectious Diseases, 2017 In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS).
Eleonora De Bellis +11 more
doaj +5 more sources
Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents [PDF]
Cancer Control, 2022 Introduction The prototype DNA hypomethylating agents 5-azacytidine (5AC) and decitabine (DAC) are currently FDA-approved for treatment of blood and bone marrow disorders like myelodysplastic syndrome.
Sridhar A Malkaram +7 more
doaj +3 more sources
Meta-analysis on hypomethylating agents in myelodysplastic syndromes
Haematologica, 2010 The addition of hypomethylating agents into the armatorium against myelodysplastic syndromes (MDS) is commonly accepted as a promising new therapeutic option in this otherwise frustrating field.
Christine Herbst +2 more
doaj +3 more sources
Immunological effects of hypomethylating agents [PDF]
Expert Review of Hematology, 2017 Epigenetic changes resulting from aberrant methylation patterns are a recurrent observation in hematologic malignancies. Hypomethylating agents have a well-established role in the management of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.
Katherine E. Lindblad +3 more
openaire +2 more sources
Clinical update on hypomethylating agents [PDF]
International Journal of Hematology, 2019 Hypomethylating agents (HMAs), azacitidine and decitabine, are standards of care in higher-risk myelodysplastic syndromes and in acute myeloid leukemia patients ineligible for intensive therapy. Over the last 10 years, research efforts have sought to better understand their mechanism of action, both at the molecular and cellular level.
Matthieu, Duchmann, Raphael, Itzykson
openaire +2 more sources
Mitoxantrone—A Hypomethylating Agent? [PDF]
Cancer Biology & Therapy, 2003 Commentary to: Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells Belinda S. Parker, Suzanne M. Cutts, Abraham Nudelman, Ada Rephaeli, Don R.
Allen S. Yang, Jean-Pierre J. Issa
openaire +1 more source
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents. [PDF]
Eur J HaematolABSTRACT Acute myeloid leukemia (AML) in elderly patients presents a major therapeutic challenge, as many are deemed unfit for intensive chemotherapy due to age, comorbidities, or frailty. Venetoclax in combination with hypomethylating agents (HMA) has emerged as a standard‐of‐care for this population, yet outcomes remain heterogeneous and predictive ...
Vigna E +11 more
europepmc +2 more sources
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]
, 2017 Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S. +3 more
core +1 more source
Mediterranean Journal of Hematology and Infectious Diseases, 2016 Objectives: Low-dose cytarabine (LD-AraC) is still regarded as the standard of care in elderly patients with acute myeloid leukemia (AML) ‘unfit’ for intensive chemotherapy.
Maël Heiblig +12 more
doaj +1 more source